Literature DB >> 27246720

Pancreatic MRI for the surveillance of cystic neoplasms: comparison of a short with a comprehensive imaging protocol.

Raffaella Maria Pozzi-Mucelli1, Irina Rinta-Kiikka2, Katharina Wünsche3, Johanna Laukkarinen4, Knut Jørgen Labori5, Kim Ånonsen6, Caroline Verbeke7,8, Marco Del Chiaro9, Nikolaos Kartalis10.   

Abstract

OBJECTIVES: The study aims were to evaluate: (1) whether a short-protocol (SP) MRI for the surveillance of pancreatic cystic neoplasms (PCN) provides equivalent clinical information as a comprehensive-protocol (CP), and (2) the cost reduction from substituting CP with SP for patient surveillance.
METHODS: This retrospective study included 154 consecutive patients (median age: 66, 52 % men) with working-diagnosis of PCN and available contrast-enhanced MRI/MRCP. Three radiologists evaluated independently two imaging sets (SP/CP) per patient. The CP included: T2-weighted (HASTE/MRCP), DWI and T1-weighted (chemical-shift/pre-/post-contrast) images [acquisition time (AT) ≈ 35 min], whereas the SP included: T2-weighted HASTE and T1-weighted pre-contrast images (AT ≈ 8 min). Mean values of largest cyst/main pancreatic duct diameter (DC/DMPD) were compared. Agreement regarding presence/absence of cystic/MPD mural nodules (MNC/MNMPD), inter-observer agreement and cost differences between SP/CP were calculated.
RESULTS: For DC and DMPD, mean values with SP/CP were 21.4/21.7 mm and 3.52/3.58 mm, while mean differences SP-CP were 0.3 mm (p = 0.02) and 0.06 mm (p = 0.12), respectively. For presence/absence of MNC and MNMPD, SP/CP coincided in 93 % and 98 % of cases, respectively. Inter-observer agreement was strong for SP/CP. SP-cost was 25 % of CP-cost.
CONCLUSIONS: For the surveillance of PCN, short-protocol MRI provides information equivalent to the more time-consuming and costly comprehensive-protocol. KEY POINTS: • Pancreatic cystic neoplasms (PCN) are increasingly diagnosed in the general population. • Multiple imaging controls are recommended for the surveillance of patients with PCN. • Short and comprehensive MRI-protocols are equivalent for decision-making in PCN under surveillance. • Evaluation of imaging risk factors in PCNs is comparable with both MRI-protocols. • Use of the short MRI-protocol may rationalise healthcare resources.

Entities:  

Keywords:  Cysts; Interdisciplinary communication; Magnetic Resonance Imaging; Neoplasms; Pancreas

Mesh:

Year:  2016        PMID: 27246720     DOI: 10.1007/s00330-016-4377-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  19 in total

1.  Incidental pancreatic cysts on 3D turbo spin echo magnetic resonance cholangiopancreatography: prevalence and relation with clinical and imaging features.

Authors:  Rossano Girometti; Sergio Intini; Giovanni Brondani; Giuseppe Como; Francesco Londero; Fabrizio Bresadola; Chiara Zuiani; Massimo Bazzocchi
Journal:  Abdom Imaging       Date:  2011-04

2.  Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee.

Authors:  Lincoln L Berland; Stuart G Silverman; Richard M Gore; William W Mayo-Smith; Alec J Megibow; Judy Yee; James A Brink; Mark E Baker; Michael P Federle; W Dennis Foley; Isaac R Francis; Brian R Herts; Gary M Israel; Glenn Krinsky; Joel F Platt; William P Shuman; Andrew J Taylor
Journal:  J Am Coll Radiol       Date:  2010-10       Impact factor: 5.532

3.  Cystic pancreatic neoplasms: observe or operate.

Authors:  Kristine S Spinelli; Travis E Fromwiller; Roger A Daniel; James M Kiely; Attila Nakeeb; Richard A Komorowski; Stuart D Wilson; Henry A Pitt
Journal:  Ann Surg       Date:  2004-05       Impact factor: 12.969

4.  Comparative performance of MDCT and MRI with MR cholangiopancreatography in characterizing small pancreatic cysts.

Authors:  Nisha I Sainani; Anuradha Saokar; Vikram Deshpande; Carlos Fernández-del Castillo; Peter Hahn; Dushyant V Sahani
Journal:  AJR Am J Roentgenol       Date:  2009-09       Impact factor: 3.959

5.  Cystic neoplasms of the pancreas and tumor-like lesions with cystic features: a review of 418 cases and a classification proposal.

Authors:  M Kosmahl; U Pauser; K Peters; B Sipos; J Lüttges; B Kremer; G Klöppel
Journal:  Virchows Arch       Date:  2004-06-08       Impact factor: 4.064

Review 6.  Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.

Authors:  Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Marie-France Bellin; Michele Bertolotto; Georg Bongartz; Olivier Clement; Peter Leander; Gertraud Heinz-Peer; Peter Reimer; Fulvio Stacul; Aart van der Molen; Judith A W Webb
Journal:  Eur Radiol       Date:  2012-08-04       Impact factor: 5.315

7.  Prevalence of unsuspected pancreatic cysts on MDCT.

Authors:  Thomas A Laffan; Karen M Horton; Alison P Klein; Bruce Berlanstein; Stanley S Siegelman; Satomi Kawamoto; Pamela T Johnson; Elliot K Fishman; Ralph H Hruban
Journal:  AJR Am J Roentgenol       Date:  2008-09       Impact factor: 3.959

Review 8.  MR imaging techniques for pancreas.

Authors:  Temel Tirkes; Christine O Menias; Kumaresan Sandrasegaran
Journal:  Radiol Clin North Am       Date:  2012-05       Impact factor: 2.303

9.  An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis.

Authors:  Bin Zhang; Long Liang; Wenbo Chen; Changhong Liang; Shuixing Zhang
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

10.  Revisiting the risks of MRI with Gadolinium based contrast agents-review of literature and guidelines.

Authors:  Aurang Z Khawaja; Deirdre B Cassidy; Julien Al Shakarchi; Damian G McGrogan; Nicholas G Inston; Robert G Jones
Journal:  Insights Imaging       Date:  2015-08-08
View more
  12 in total

Review 1.  The diagnosis and management of intraductal papillary mucinous neoplasms of the pancreas: has progress been made?

Authors:  Jenny Lim; Peter J Allen
Journal:  Updates Surg       Date:  2019-06-07

2.  Are pancreatic IPMN volumes measured on MRI images more reproducible than diameters? An assessment in a large single-institution cohort.

Authors:  Pallavi Pandey; Ankur Pandey; Farnaz Najmi Varzaneh; Mounes Aliyari Ghasabeh; Daniel Fouladi; Pegah Khoshpouri; Nannan Shao; Manijeh Zarghampour; Ralph H Hruban; Marcia Canto; Anne Marie O'Broin-Lennon; Ihab R Kamel
Journal:  Eur Radiol       Date:  2018-02-05       Impact factor: 5.315

Review 3.  Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: recommendations for Standardized Imaging and Reporting from the Society of Abdominal Radiology IPMN disease focused panel.

Authors:  Elizabeth M Hecht; Gaurav Khatri; Desiree Morgan; Stella Kang; Priya R Bhosale; Isaac R Francis; Namita S Gandhi; David M Hough; Chenchan Huang; Lyndon Luk; Alec Megibow; Justin M Ream; Dushyant Sahani; Vahid Yaghmai; Atif Zaheer; Ravi Kaza
Journal:  Abdom Radiol (NY)       Date:  2020-11-13

4.  Utility of gadolinium for identifying the malignant potential of pancreatic cystic lesions.

Authors:  Andrea S Kierans; Alexander Gavlin; Natasha Wehrli; Laura M Flisnik; Sarah Eliades; Meredith E Pittman
Journal:  Abdom Radiol (NY)       Date:  2022-02-23

5.  Side-branch intraductal papillary mucinous neoplasms of the pancreas: outcome of MR imaging surveillance over a 10 years follow-up.

Authors:  Piero Boraschi; Gaia Tarantini; Francescamaria Donati; Paola Scalise; Rosa Cervelli; Davide Caramella
Journal:  Eur J Radiol Open       Date:  2020-08-21

6.  Wireless amplified NMR detector for improved visibility of image contrast in heterogeneous lesions.

Authors:  Xianchun Zeng; Shengqiang Xu; Changyong Cao; Jian Wang; Chunqi Qian
Journal:  NMR Biomed       Date:  2018-07-16       Impact factor: 4.044

7.  European evidence-based guidelines on pancreatic cystic neoplasms.

Authors: 
Journal:  Gut       Date:  2018-03-24       Impact factor: 23.059

8.  Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.

Authors:  Michael Goggins; Kasper Alexander Overbeek; Randall Brand; Sapna Syngal; Marco Del Chiaro; Detlef K Bartsch; Claudio Bassi; Alfredo Carrato; James Farrell; Elliot K Fishman; Paul Fockens; Thomas M Gress; Jeanin E van Hooft; R H Hruban; Fay Kastrinos; Allison Klein; Anne Marie Lennon; Aimee Lucas; Walter Park; Anil Rustgi; Diane Simeone; Elena Stoffel; Hans F A Vasen; Djuna L Cahen; Marcia Irene Canto; Marco Bruno
Journal:  Gut       Date:  2019-10-31       Impact factor: 23.059

9.  Survival Analysis and Risk for Progression of Intraductal Papillary Mucinous Neoplasia of the Pancreas (IPMN) Under Surveillance: A Single-Institution Experience.

Authors:  Marco Del Chiaro; Zeeshan Ateeb; Marcus Reuterwall Hansson; Elena Rangelova; Ralf Segersvärd; Nikolaos Kartalis; Christoph Ansorge; Matthias J Löhr; Urban Arnelo; Caroline Verbeke
Journal:  Ann Surg Oncol       Date:  2016-11-07       Impact factor: 5.344

10.  Incidental pancreatic cyst: still a lot of road to cover.

Authors:  Giuseppe D'Ippolito
Journal:  Radiol Bras       Date:  2018 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.